Plethora of new agents in multiple myeloma

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients .